Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease.
Associative memory
Autosomal dominant Alzheimer’s disease
Binding
Biomarkers
Presenilin-1
Tau PET
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
21 08 2020
21 08 2020
Historique:
received:
19
03
2020
accepted:
28
07
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
25
6
2021
Statut:
epublish
Résumé
Over the past decade, visual short-term memory (VSTM) binding tests have been shown to be one of the most sensitive behavioral indicators of Alzheimer's disease (AD), especially when they require the binding of multiple features (e.g., color and shape). Recently, it has become possible to directly measure amyloid and tau levels in vivo via positron emission tomography (PET). To this point, these behavioral and neurochemical markers have not been compared in humans with AD or at risk for it. In a cross-sectional study, we compared VSTM performance to tau and amyloid concentrations, measured by PET, in individuals certain to develop AD by virtue of their inheritance of the presenilin-1 E280A mutation. These included 21 clinically unimpaired subjects and 7 subjects with early mild cognitive impairment (MCI), as well as 30 family members who were not carriers of the mutation. We found that VSTM performance correlated strongly with tau in entorhinal cortex and inferior temporal lobe, and also with amyloid when examining asymptomatic carriers only. The condition requiring binding was not preferentially linked to tau-in fact, the non-binding "shape only" condition showed a stronger relationship. The results confirm VSTM's status as an early marker of AD pathology and raise interesting questions as to the course of binding-specific versus non-binding aspects of VSTM in early AD.
Sections du résumé
BACKGROUND
Over the past decade, visual short-term memory (VSTM) binding tests have been shown to be one of the most sensitive behavioral indicators of Alzheimer's disease (AD), especially when they require the binding of multiple features (e.g., color and shape). Recently, it has become possible to directly measure amyloid and tau levels in vivo via positron emission tomography (PET). To this point, these behavioral and neurochemical markers have not been compared in humans with AD or at risk for it.
METHODS
In a cross-sectional study, we compared VSTM performance to tau and amyloid concentrations, measured by PET, in individuals certain to develop AD by virtue of their inheritance of the presenilin-1 E280A mutation. These included 21 clinically unimpaired subjects and 7 subjects with early mild cognitive impairment (MCI), as well as 30 family members who were not carriers of the mutation.
RESULTS
We found that VSTM performance correlated strongly with tau in entorhinal cortex and inferior temporal lobe, and also with amyloid when examining asymptomatic carriers only. The condition requiring binding was not preferentially linked to tau-in fact, the non-binding "shape only" condition showed a stronger relationship.
CONCLUSIONS
The results confirm VSTM's status as an early marker of AD pathology and raise interesting questions as to the course of binding-specific versus non-binding aspects of VSTM in early AD.
Identifiants
pubmed: 32825838
doi: 10.1186/s13195-020-00660-z
pii: 10.1186/s13195-020-00660-z
pmc: PMC7442980
doi:
Substances chimiques
Amyloid beta-Peptides
0
Presenilin-1
0
tau Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
99Subventions
Organisme : NIA NIH HHS
ID : K24 AG035007
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062421
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG027435
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG046396
Pays : United States
Références
JAMA Neurol. 2015 Mar;72(3):316-24
pubmed: 25580592
J Neurosci. 2010 Jul 21;30(29):9890-7
pubmed: 20660271
Arch Gerontol Geriatr. 2019 Jul - Aug;83:114-120
pubmed: 30999126
Nature. 2006 Mar 2;440(7080):91-5
pubmed: 16382240
Alzheimers Res Ther. 2013 Nov 21;5(6):58
pubmed: 24257331
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S161-70
pubmed: 26402080
Neuropsychologia. 2015 Jul;73:169-75
pubmed: 26002757
Percept Psychophys. 2002 Nov;64(8):1260-80
pubmed: 12519024
Neurobiol Aging. 2011 Jul;32(7):1219-30
pubmed: 19713001
Neuropsychologia. 2011 Jun;49(7):1943-52
pubmed: 21435348
Brain. 2015 May;138(Pt 5):1355-69
pubmed: 25762465
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Cortex. 2016 May;78:150-164
pubmed: 27085491
JAMA Neurol. 2014 Nov;71(11):1379-85
pubmed: 25222039
Brain. 2010 Sep;133(9):2702-13
pubmed: 20624814
JAMA Neurol. 2018 May 1;75(5):548-556
pubmed: 29435558
Neuropsychologia. 2014 Jan;52:27-36
pubmed: 24120612
Neurology. 2015 Jul 7;85(1):56-62
pubmed: 26048028
J Alzheimers Dis. 2018;65(1):107-115
pubmed: 30040714
Nature. 1997 Nov 20;390(6657):279-81
pubmed: 9384378
Alzheimers Dement. 2016 Mar;12(3):292-323
pubmed: 27012484
Neurosci Bull. 2014 Apr;30(2):359-66
pubmed: 24627329
Lancet Neurol. 2012 Dec;11(12):1057-65
pubmed: 23137949
Arch Neurol. 2012 Jun;69(6):709-13
pubmed: 22529247
Neurology. 2017 Oct 3;89(14):1464-1470
pubmed: 28878053
J Neurosci. 2009 Oct 7;29(40):12686-94
pubmed: 19812343
Ann Neurol. 2011 Jan;69(1):181-92
pubmed: 21280088
J Neurosci. 2017 Apr 19;37(16):4323-4331
pubmed: 28314821
Ann Neurol. 2016 Jan;79(1):110-9
pubmed: 26505746
Lancet Neurol. 2011 Mar;10(3):213-20
pubmed: 21296022
Alzheimers Res Ther. 2017 Apr 17;9(1):27
pubmed: 28412978
J Exp Psychol Hum Percept Perform. 2001 Feb;27(1):92-114
pubmed: 11248943
Nat Neurosci. 2018 Mar;21(3):424-431
pubmed: 29403032
Neuropsychologia. 2011 May;49(6):1393-400
pubmed: 21256143
Psychol Bull. 1973 Jun;79(6):380-5
pubmed: 4707457
Ann Neurol. 2011 Jun;69(6):1032-42
pubmed: 21437929
J Neurol. 2010 Jul;257(7):1160-9
pubmed: 20162428
J Alzheimers Dis. 2017;60(4):1451-1459
pubmed: 29036824
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248